Home > Insider Trading > Filing (0001235802-22-000113)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1453593	Xtant Medical Holdings Inc.	XTNT	Biological Products, (No Disgnostic Substances) (2836)	205313323

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1559834	G. Stavros Vizirgianakis	664 Cruiser Lane Belgrade MT 59714		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.000001 Par Value	Acquisiton	2022-10-07	2,264,861	$0.48	5,850,716	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant	Acquisiton	2022-10-07	566,214	$0.00	566,214	$0.48

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
566,214	2022-10-07	2027-08-25	No	4	P	Direct

Footnotes

These shares were issued in a second and final tranche of a private placement pursuant to a securities purchase agreement by and among Xtant Medical Holdings, Inc. and several accredited investors.
Includes 70,776 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date.
This warrant was issued in a second and final tranche of a private placement pursuant to the securities purchase agreement by and among Xtant Medical Holdings, Inc. and several accredited investors.
This total does not include a warrant to purchase 878,770 shares of common stock issued on August 25, 2022. Such warrant was immediately exercisable as of the date of issuance and previously reported by the Reporting Person on a Form 4 filed with the Securities and Exchange Commission on August 26, 2022.